MetaVia Transforms Focus on Cardiometabolic Treatments
Today, the biotechnology company NeuroBo Pharmaceuticals, Inc. has made a significant shift in its branding and focus, announcing a name change to MetaVia Inc. This strategic realignment is aligned with the company's vision of addressing cardiometabolic diseases, a pressing health concern in modern society. The corporate name change is part of a broader strategy to enhance its clinical capabilities and to prepare for important milestones in its development pipeline.
New Ticker Symbol
As MetaVia embarks on this new chapter, it will also adopt a new Nasdaq ticker symbol, MTVA, which will be active starting on the Effective Date. This shift aims to reflect the company's renewed commitment to developing advanced therapies targeting cardiometabolic conditions, which have been recognized as key areas for unmet medical need.
Exciting Developments Ahead
MetaVia is well-positioned financially to pursue its ambitious goals. Notably, the company successfully raised up to $70 million in a financing round earlier this year, securing resources necessary to advance its clinical programs. The funding includes $20 million in upfront cash with an additional $50 million linked to clinical milestones. This financial support is vital as it allows MetaVia to accelerate the research and development of its next-generation therapies.
Key Therapeutic Initiatives
The company's innovative lead products under development include DA-1726 and DA-1241. DA-1726 is a novel dual-agonist that has shown promising results in preclinical studies targeting obesity by balancing the activation of glucagon-like peptide-1 receptors, which controls insulin and appetite. Additionally, clinical trials for DA-1241, a novel GPR119 agonist, are set to report critical data on its efficacy and safety in treating metabolic dysfunction-related steatohepatitis (MASH) very soon. The expectation of clinical data releases adds excitement and anticipation among stakeholders.
About MetaVia Inc.
MetaVia, formerly known as NeuroBo Pharmaceuticals, is dedicated to pioneering breakthroughs in the treatment of cardiometabolic diseases. The company's primary focus remains on developing therapies to combat obesity and the associated metabolic disorders. DA-1726 and DA-1241 are central to their research efforts and are anticipated to offer significant benefits over current treatment options due to their innovative mechanisms. DA-1726's function as a dual agonist has the potential to enhance weight loss and reduce appetite, thereby standing out among typical GLP-1 agonists. Moreover, DA-1241's action in promoting critical gut peptides can lead to improvements in liver health and metabolic parameters.
Contact Information
If you seek to learn more about MetaVia, please reach out to their Chief Financial Officer, Marshall H. Woodworth, at +1-857-299-1033 for any inquiries or additional details.
Frequently Asked Questions
What prompted the name change to MetaVia?
The name change reflects the company's expanded focus on cardiometabolic diseases and aims to represent its commitment to innovative therapy development.
What are the key products in development at MetaVia?
MetaVia is currently advancing DA-1726 for obesity treatment and DA-1241 for metabolic dysfunction-associated steatohepatitis (MASH).
Is the corporate structure of MetaVia affected by the name change?
No, the name change and new ticker symbol will not impact the company's operations, management, or structure.
When will the new ticker symbol, MTVA, take effect?
The new ticker symbol MTVA will begin trading on the Nasdaq starting on the Effective Date of the name change.
How can I find out more about MetaVia's progress and clinical programs?
For further information regarding MetaVia's initiatives, stakeholders can contact the company directly or monitor updates through their official communications.
